Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Zoeken op expertise, naam of affiliatie
Utility of adjuvant systemic therapy in melanoma
A. M.M. Eggermont
, A. Testori
, J. Marsden
, P. Hersey
, I. Quirt
, T. Petrella
, H. Gogas
, R. M. MacKie
, A. Hauschild
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
31
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Utility of adjuvant systemic therapy in melanoma'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Interferon-α (IFN-α)
100%
Melanoma
100%
Adjuvant Systemic Therapy
100%
Clinical Trials
40%
Chemotherapy
20%
Meta-analysis
20%
Clinically Significant
20%
Europe
20%
Overall Survival
20%
Adjuvant Therapy
20%
In(III)
20%
Relapse-free Survival
20%
Effective Compounds
20%
Response Predictors
20%
Treatment Duration
20%
Disease-free Survival
20%
Stage II-III
20%
Control Arm
20%
High-dose Interferon
20%
Stage IV Melanoma
20%
Immunostimulant
20%
Overall Survival Benefit
20%
Dermatologist
20%
AJCC Stage
20%
Interferon Therapy
20%
Central Europe
20%
Northwest Europe
20%
Mediterranean Europe
20%
Medicine and Dentistry
Adjuvant Therapy
100%
Interferon
100%
Melanoma
100%
Clinical Trial
28%
Disease
28%
Overall Survival
28%
Biological Marker
14%
Meta-Analysis
14%
Low Drug Dose
14%
Arm
14%
Recurrence Free Survival
14%
Drug Megadose
14%
Treatment Duration
14%
Disease Free Survival
14%
Immunostimulating Agent
14%
Chemotherapy
14%
Nursing and Health Professions
Melanoma
100%
Adjuvant Therapy
100%
Interferon
100%
Disease
28%
Overall Survival
28%
Meta Analysis
14%
Treatment Duration
14%
Biological Marker
14%
Low Drug Dose
14%
Drug Megadose
14%
Recurrence Free Survival
14%
Disease Free Survival
14%
Dermatologist
14%
Immunostimulating Agent
14%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Interferon
100%
Clinical Trial
28%
Disease
28%
Overall Survival
28%
Biological Marker
14%
Chemotherapy
14%
Recurrence Free Survival
14%
Disease Free Survival
14%
Immunostimulant
14%
Immunology and Microbiology
interferon
100%
Overall Survival
28%
Recurrence Free Survival
14%
Drug Megadose
14%
Arm
14%
Disease Free Survival
14%
Low Drug Dose
14%
Immunostimulant
14%